Ablynx NV | CIK:0001617582 | 3

  • Filed: 4/5/2018
  • Entity registrant name: Ablynx NV (CIK: 0001617582)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1617582/000119312518108717/0001193125-18-108717-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1617582/000119312518108717/ablx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001617582
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfOperatingSegmentsExplanatory

    6 SEGMENT INFORMATION

    The Company does not distinguish different operating segments.

    The income was derived from five pharmaceutical partners, namely AbbVie, Merck KGaA, Merck & Co., Inc., Sanofi and Novo Nordisk. Moreover, in 2017 more than 80% of the income originated from three parties, one party was responsible for 29% of the income, two other parties represented 27% each.

    In 2016 more than 85% of the income originated from three parties, one party was responsible for more than 40% of the income, two other parties represented between 19% and 25% each. In 2015, one party represented more than 50% of the revenues, two other parties represented between 15% and 23% each.